OPGEN INC (OPGN)

Company Profile

OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. The company is headquartered in Rockville, Maryland and currently employs 100 full-time employees. The company went IPO on 2015-05-05. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Company’s product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE- in vitro diagnostics (IVD)-marked polymerase chain reaction (PCR)-based severe acute respiratory syndrome (SARS)-CoV-2 test kit. The Company’s subsidiaries include Curetis GmbH and Ares Genetics GmbH.

Company Info

OPGEN INC

9717 Key West Avenue, Suite 100

Rockville MARYLAND 20878

P: 13018699683

CEO: Oliver Schacht

Employees: 100

Website: https://opgen.com/